APPOINTMENT 1 / Jan 2022 — Present
Senior vice-president and chief data officer
Mirebrook Pharmacy & Beauty Inc.
- Sector
- Pharmacy, beauty and front-store health retail
- Ownership
- Listed on the Toronto Stock Exchange; widely held
- Company scale
- C$8.3bn revenue in fiscal 2025 (C$3.6bn dispensary, C$4.7bn front store)
- Employees
- About 29,000 across corporate and franchised stores, distribution and head office
- Geography
- 648 stores in nine provinces, including 173 pharmacist-owned stores in Québec; head office in Mississauga, Ontario
- Reporting to
- President and chief executive officer; presents quarterly to the board's audit and risk committee with the chief privacy officer
- Team
- 6 direct reports; 186 colleagues in data engineering, analytics and data science, data products and data governance
- Financial scope
- C$54m operating and C$19m capital budget (2026); data and analytics behind a partner network earning C$152m (2025) and a loyalty programme of 10.6m active members
Mandate
Turn a capable analytics department into an accountable data function: own governance and the loyalty data platform, set the rules for personalisation and supplier data use, and give the board a clear account of data risk.
Outcomes
- Separated consent for personalised offers and supplier advertising for all members; 61% and 44% agreed, and privacy complaints fell from 1,140 to 310 a year.
- Allocated scarce children's fever medicine by need in 2022–23; 590 of 648 stores kept stock at least five days in seven during the hardest weeks.
- Launched a supplier clean room excluding 38 health-inference categories; partner network revenue reached C$152m in 2025 after a C$23m shortfall against plan in 2024.
- Reduced front-store shrink from 2.3% to 1.8% of front-store sales without biometric identification.
- Raised peak-week availability of 212 essential health products from 91% to 97% between the 2023–24 and 2024–25 winters.
Decisions in context
The chief data officer role was created in January 2022, when our chief executive concluded that decisions about customer data were being made in too many places. I took over governance, the data side of Mirebrook Circle and the analytics behind the partner network, and moved from reporting to the chief financial officer to reporting to him. Within the first year we faced a national shortage of children's fever medicine and the arrival of stricter consent rules in Québec, and both forced decisions that I would otherwise have approached more slowly. Since then the work has been to make our refusals explicit: the consent questions, the health-inference register, the clean room rules, the limits on loss analytics and the published rules for personalised offers. I present to the audit and risk committee each quarter, with our chief privacy officer, and I am not a director of the company.
Reason for the move
Current appointment; completing the essentials forecasting programme and the board's review of the partner network.